Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2026 Nov 2;16:1949632. doi: 10.3389/fonc.2026.1949632

Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma

Xiaozhou Xie 1,2,†, Jie Li 3,†, Yuchen Jia 1,2,†, Yuxi Zhang 1,2, Jiongdi Lu 1,2, Feng Cao 1,2, Fei Li 1,2,*
PMCID: PMC13770813  PMID: 43041312

Abstract

Background

Minichromosome maintenance protein 7 (MCM7), an integral component of the DNA replication licensing complex, has been implicated in diverse human malignancies. However, a holistic, multi-omics evaluation of its oncogenic repertoire across a broad spectrum of cancers remains conspicuously absent. We comprehensively characterized the expression landscape, prognostic significance, genetic aberrations, and immunomodulatory correlations of MCM7 across 33 cancer types, and further experimentally corroborated its functional and mechanistic roles in lung adenocarcinoma (LUAD).

Methods

We leveraged multi-omics datasets from TCGA, GTEx, CPTAC, and HPA to assess MCM7 expression, survival outcomes, and genomic alterations. Correlative analyses were performed with tumor mutational burden, microsatellite instability, cancer-associated fibroblast infiltration, immune checkpoints, and RNA modification regulators. Functionally, MCM7 was silenced via siRNA in LUAD cell lines, followed by comprehensive assessments of proliferation, cell cycle, migration, invasion, and epithelial-mesenchymal transition. Mechanistic exploration was conducted via RNA-sequencing and western blotting.

Results

MCM7 is markedly upregulated in most malignant tumors, and its elevated expression is closely associated with poor survival prognosis. Copy number amplification was identified as the predominant genetic alteration, while the R72C/H mutation was specifically linked to dismal outcomes in glioblastoma. Notably, MCM7 expression displayed robust positive correlations with TMB, MSI, the immune checkpoint HMGB1, and the m5C reader ALYREF in most cancer types. Functional enrichment reaffirmed its canonical involvement in cell cycle and DNA replication. In vitro, MCM7 knockdown drastically abrogated LUAD cell viability, colony formation, and metastatic capacity, while inducing G0/G1 phase arrest and reversing EMT phenotypes. Mechanistically, transcriptomic and experimental validations convergently revealed that MCM7 silencing exerts its anti-tumor effects via suppression of the JAK-STAT3 signaling cascade.

Conclusion

Our findings establish MCM7 as a bona fide pan cancer oncogenic determinant and a promising diagnostic/prognostic biomarker. Furthermore, we unveil a novel mechanistic axis linking MCM7 to JAK STAT3 driven inflammatory signaling in LUAD, offering a pre-clinical hypothesis for targeting MCM7 in combination with immunotherapeutic or JAK/STAT inhibitory regimens, although in-vivo validation and toxicity assessment remain essential.

Keywords: human cancer, immune infiltration, lung adenocarcinoma, MCM7, survival prognosis

1. Introduction

Cancer represents a heterogeneous group of diseases driven by aberrant cell cycle regulation and uncontrolled DNA replication, hallmarks that enable sustained proliferation and malignant progression (1). Among the critical mediators of DNA replication licensing, minichromosome maintenance protein 7 (MCM7) is an essential component of the replicative helicase complex, which governs the initiation and elongation of DNA synthesis and ensures accurate genome duplication during cell division (2). Dysregulation of MCM7 has emerged as a critical molecular event in human malignancies, and its aberrant overexpression or gene amplification is associated with uncontrolled proliferation, enhanced invasiveness, and poor clinical outcomes (3, 4).

Mounting evidence has established MCM7 as a pivotal oncogenic factor in diverse cancer types. MCM7 promotes cell proliferation, modulates caspase-3/7 activity, and facilitates the progression of renal cell carcinoma (5). MCM7 supports the stemness of bladder cancer stem-like cells by enhancing autophagic flux (6). MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma (7). MCM7 may also serve as a useful predictive biomarker for patients with gastric cancer, breast cancer, and prostate cancer (8–11). Notably, in a 2023 study published in Nature by Tirosh et al., a comprehensive pan-cancer single-cell RNA-sequencing dataset was established, in which MCM7 was identified as the best-performing diagnostic biomarker in malignant tumor cells, with the optimal combined score for balancing sensitivity and specificity (12).

Most existing research on MCM7 only focuses on single tumor types, lacking a multi-omics panoramic evaluation covering transcriptome, proteome, genetic variation, and tumor microenvironment crosstalk across all major human malignancies. Moreover, although prior literature has preliminarily linked MCM7 to cell cycle and DNA replication processes, few studies have excavated its non-canonical functions beyond genome replication, especially its regulatory role in inflammatory and immune signaling pathways within the tumor microenvironment. Lung malignancy remains the leading cause of cancer-related mortality worldwide (13, 14). As a predominant subtype of non-small cell lung cancer, lung adenocarcinoma (LUAD) has exhibited an increasing incidence in recent years (15). Previous studies have revealed that MCM7 is significantly upregulated in lung cancer tissues, and its overexpression is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC) (16, 17). However, the precise molecular mechanisms by which MCM7 drives the malignant progression of LUAD still require rigorous cellular functional verification and mechanistic exploration at the transcriptomic level. Although previous literature has preliminarily linked MCM7 to cell cycle and DNA replication processes, few studies have explored its non-canonical functions beyond genomic replication, especially its regulatory roles in inflammatory and immune signaling pathways within the tumor microenvironment.

The present study conducted a systematic pan-cancer multi-omics analysis of MCM7 based on TCGA, GTEx, CPTAC, HPA and other public databases. We profiled the mRNA and protein expression spectrum of MCM7 across 33 human cancers, evaluated its prognostic value, characterized the landscape of its genetic alterations, and dissected its correlations with tumor mutational burden (TMB), microsatellite instability (MSI), cancer-associated fibroblast infiltration, immune checkpoint molecules and RNA modification regulators. Functional enrichment analysis was further performed to uncover core biological programs controlled by MCM7. On the basis of pan-cancer bioinformatic findings, we selected LUAD as a representative tumor model to carry out a series of in vitro functional experiments. Combined with RNA-seq transcriptome sequencing and western blot validation, we further revealed that MCM7 exerts oncogenic effects via activating the JAK-STAT3 signaling axis in LUAD cells.

Collectively, this work provides a comprehensive pan-cancer atlas of MCM7’s tumorigenic functions, confirms its value as a broad-spectrum diagnostic and prognostic biomarker for human cancers, and clarifies its novel mechanistic link with JAK-STAT3 immune-inflammatory signaling in LUAD. Our research provides theoretical clues for exploring putative MCM7-targeted strategies, and generates hypothetical suggestions for combinatorial regimens coupling MCM7 inhibition with immune-checkpoint blockers or JAK-STAT-pathway antagonists; these ideas remain to be experimentally validated.

2. Materials and methods

2.1. Gene and protein expression analysis

The “Gene_DE” module of Tumor Immune Estimation Resource version 2 (TIMER2.0, https://compbio.cn/timer2/) was used to analyze the mRNA expression differences of MCM7 between tumor tissues and corresponding normal tissues across various cancer types based on the TCGA dataset. For cancer types without matched normal tissues in TCGA, the Gene Expression Profiling Interactive Analysis 2 (GEPIA2, http://gepia2.cancer-pku.cn/#analysis) database (18) was applied with the cutoff criteria of |log2FC| = 1 and q-value < 0.01 to supplement the expression comparison of MCM7 between tumor and normal tissues from TCGA and GTEx databases, and the corresponding box plots were generated.

The Human Protein Atlas (HPA, https://www.proteinatlas.org/) database was utilized to explore the protein expression profiles of MCM7 in human tumor tissues and tumor cells. In addition, the “Stage Plot” module of GEPIA2 was performed to investigate the correlation between MCM7 expression and pathological stages of various tumors in the TCGA database. All gene expression data for visualization were normalized by log2(TPM + 1) transformation. In addition, the protein expression of MCM7 in tumors was analyzed using the UALCAN database (https://ualcan.path.uab.edu/index.html) (19).

2.2. Survival prognosis analysis

The Survival Map module of GEPIA2 was used to obtain overall survival (OS) and disease-free survival (DFS) data across all cancer types from the TCGA database. The median expression level was set as the cutoff value to stratify patients into high- and low-MCM7-expression groups, survival curves were generated via the survival analysis module of GEPIA2.

RNA-seq data and corresponding clinical information of pan-cancer patients were downloaded from the TCGA database. Gene expression data were converted to TPM format and normalized by log2(TPM + 1) transformation. Only samples with both RNA-seq profiles and complete clinical data were retained. Univariate Cox regression analysis was performed to calculate hazard ratios (HR) with 95% confidence intervals (CIs), and P-values were determined by the Log-rank test, followed by construction of the prognostic forest plot.

2.3. Genetic alteration analysis

We selected “TCGA Pan Cancer Atlas Studies” in the “Quick select” section of the cBioPortal website (https://www.cbioportal.org/) to analyze the genetic alterations of MCM7 in TCGA tumors. We observed the frequency of MCM7 alterations and mutation types in the “Cancer Types Summary” module. In addition, the “Mutations” module provides information on the mutation sites of MCM7. We also analyzed the survival information of tumor patients with MCM7 gene alterations in the “Comparison/Survival” module and generated survival maps.

2.4. Immune infiltration and RNA modification analysis

The Immune module of the TIMER2 was utilized to assess the immune infiltration of cancer-associated fibroblasts correlated with MCM7 via four algorithms, including EPIC, MCPCOUNTER, XCELL, and TIDE. We downloaded the uniformly standardized pan-cancer dataset from the UCSC database (https://xenabrowser.net/), and extracted the expression profiles of MCM7, 60 immune checkpoint pathway marker genes, 150 immune pathway marker genes, and 44 RNA modified genes across all samples. All expression values were normalized by log2(x+0.001) transformation. Subsequently, Pearson correlation analysis was performed between MCM7 and the marker genes of immune pathways.

2.5. MCM7-related gene enrichment analysis

We constructed the protein-protein interaction (PPI) network of MCM7 using the STRING database (https://cn.string-db.org/), from which 50 experimentally validated interacting proteins of MCM7 were obtained. The top 100 genes with expression patterns similar to MCM7 were screened via the GEPIA2. Furthermore, Pearson correlation analysis was performed on the top six genes highly correlated with MCM7 using the “Correlation Analysis” module of GEPIA2, and correlation heatmaps were plotted accordingly.

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on the combined gene lists derived from the above two datasets using the “clusterProfiler” package in R software. Enrichment results were visualized with the ggplot2 package, and P < 0.05 was defined as statistically significant.

2.6. Cell culture

Human bronchial epithelial (HBE), A549, H1299 and PC-9 cell lines were purchased from the American Type Culture Collection (ATCC). HBE, A549 and PC-9 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco), whereas H1299 cells were maintained in RPMI-1640 medium (Gibco). All culture media were supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (10 U/mL, Thermo Fisher). Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2.

2.7. Cell transfection

MCM7-targeting siRNA was purchased from Mailgene (Beijing, China). A549 and H1299 cells were seeded into six-well plates and transfected with Lipofectamine 2000 (Thermo Fisher Scientific) at 70% confluence according to the manufacturer’s protocol. Knockdown efficiency was evaluated at 48 h post-transfection.

2.8. Western blot

Cells were lysed using RIPA lysis buffer. After centrifugation, the supernatant was collected. Total proteins were separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% non-fat dried milk, followed by overnight incubation at 4 °C with primary antibodies against β-actin (66009-1-Ig), MCM7 (Proteintech, 11225-1-AP), CDK2 (ABclonal, A0094), Cyclin D1 (Abmart, T55404), Cyclin E1 (Abmart, TA0144), E-Cadherin (abcam, ab76055), N-Cadherin (Servicebio, GB12135), Vimentin (Servicebio, GB11192), JAK1 (ucallm, WR4438), p-JAK1 (Selleck, F3783), JAK2 (ABclonal, A28566), p-JAK2 (Selleck, F4153), STAT3 (Selleck, F0200), p-STAT3 (Selleck, F1212). Subsequently, the membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized with an ECL chemiluminescence detection kit, and band intensities were quantified using ImageJ software.

2.9. CCK-8 assays

The cell proliferation capacity was detected using Cell Counting Kit-8 (CCK8) (Dojindo, Japan) reagent and evaluated on day 1, day 2, day 3, day 4 and day 5.

2.10. Colony formation assays

A549 and H1299 cells were seeded into six-well plates at low density after MCM7 siRNA transfection. Cells were cultured for approximately 10–14 days until visible colonies formed. Colonies were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of colonies was calculated using ImageJ.

2.11. Wound healing assays

For the wound healing assay, transfected A549 and H1299 cells were seeded into six-well plates and grown to full confluence. A straight scratch was created using a sterile pipette tip. After washing off detached cells, cells were cultured in serum free medium. The migration rate was calculated by measuring the wound area using ImageJ software.

2.12. Transwell assays

For the migration assay, transfected A549 and H1299 cells were suspended in serum free medium and seeded into the upper chambers. Medium containing 10% FBS was added to the lower chambers as a chemoattractant. After 24 h of incubation, non-migratory cells on the upper surface were wiped off with a cotton swab. Migrated cells were fixed, stained with crystal violet, and counted under a microscope. For the invasion assay, the upper chambers were pre-coated with matrigel before cell seeding. Subsequent procedures were consistent with those of the migration assay.

2.13. Evaluation of the cell cycle by flow cytometry

Transfected A549 and H1299 cells were harvested and fixed in 70% ethanol overnight at 4 °C. A working staining solution was prepared using the cell cycle detection kit (Keygen Biotech). After centrifugation, the supernatant was removed, and the cell pellet was resuspended in 500 μL of the working solution. Following 30 min of staining in the dark, cell cycle distribution was analyzed by flow cytometry, and the acquired data were processed with FlowJo software.

2.14. Statistical analysis

Statistical analyses were performed using GraphPad Prism 8 (Version 8.0.1) and R software (Version 4.5.0). Data were collected from at least three independent experimental replicates and analyzed by t-test or one-way ANOVA. A value of p < 0.05 was considered statistically significant.

3. Results

3.1. Pan-cancer expression analysis of MCM7

We analyzed the expression of MCM7 across different cancer types in the TCGA database using the TIMER2.0 database. As shown in Figure 1A, MCM7 was significantly upregulated in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and Neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC) compared with corresponding normal tissues, whereas its expression was markedly downregulated in kidney Chromophobe (KICH).

Figure 1.

Panel A shows box plots comparing MCM7 expression across multiple tumor and normal tissue types in the TCGA dataset, with red representing tumors and blue representing normals. Panel B presents box plots comparing MCM7 expression in selected cancers and normals from the TCGA+GTEx dataset. Panel C displays box plots of protein expression for normal and tumor samples in several cancer types from the CPTAC dataset. Panel D contains circular immunohistochemistry images demonstrating MCM7 expression in normal and cancer tissues from the HPA dataset. Panel E shows violin plots of MCM7 expression grouped by clinical stage across various cancers in the TCGA dataset.

Expression of MCM7 in pan-cancer. (A) Differential expression of MCM7 mRNA in various tumor and normal tissues derived from the TCGA database. (B) Differential expression of MCM7 mRNA in various tumor and normal tissues derived from the TCGA and GTEx databases. (C) Differential protein expression of MCM7 in various tumor and normal tissues from the CPTAC database. (D) Immunohistochemical staining of MCM7 in various tumor tissues and their matched normal tissues based on the HPA database. (E) Correlation between MCM7 expression and clinicopathological staging in various tumors from the TCGA database.

To supplement normal tissue data for cancer types lacking matched normal controls in TCGA, we incorporated normal tissue data from the GTEx database to further analyze the expression differences of MCM7 between tumor and normal tissues. We found that MCM7 was significantly upregulated in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), brain lower grade glioma (LGG), sarcoma (SARC), testicular germ cell tumors (TGCT), and thymoma (THYM), whereas it was downregulated in acute myeloid leukemia (LAML) (Figure 1B).

We analyzed the protein levels of MCM7 in the UALCAN database, and found that the MCM7 protein expression level was significantly higher in tumor tissues including breast cancer, clear cell RCC, colon cancer, GBM, HNSC, LIHC, LUAD, LUSC, ovarian cancer, pancreatic adenocarcinoma (PAAD), and UCEC than in corresponding normal tissues (Figure 1C). This finding was further validated by immunohistochemistry (Figure 1D). We then used the GEPIA2 to analyze the correlation between MCM7 expression and the tumor pathological stage and observed changes in MCM7 expression at different stages of adrenocortical carcinoma (ACC), BRCA, KICH, LIHC, LUAD, and ovarian serous cystadenocarcinoma (OV). Among them, the expression of MCM7 was significantly positively correlated with tumor pathological stage in ACC, KICH and LUAD, indicating that patients with high MCM7 expression tended to have advanced clinicopathological stages and potentially poorer prognosis (Figure 1E). These multi-omics expression results demonstrate that MCM7 exhibits widespread upregulation across human cancers, indicating its conserved oncogenic expression pattern and supporting its potential pan-cancer biomarker role.

3.2. Prognostic survival analysis of MCM7 in human cancers

To explore the correlation between MCM7 expression and clinical prognosis, patients from the TCGA dataset were stratified into high- and low-expression groups based on MCM7 expression levels, and survival differences were subsequently compared. Survival analysis revealed that elevated MCM7 expression was correlated with unfavorable overall survival (OS) in ACC, KICH, LGG, LIHC, LUAD and mesothelioma (MESO). Conversely, low MCM7 expression indicated poor OS prognosis in THYM (Figure 2A). Disease-free survival (DFS) analysis further demonstrated that high MCM7 expression was associated with adverse prognosis in ACC, LGG, LIHC, MESO and PRAD (Figure 2B).

Figure 2.

Panel A presents overall survival Kaplan-Meier plots for subgroups of cancer types, color-coded and mapped to log hazard ratios in a horizontal heatmap for gene MCM7, with high and low expression groups indicated. Panel B displays disease-free survival Kaplan-Meier plots, similarly mapped to a horizontal heatmap for the same gene and cancer types, summarizing differences in survival based on gene expression.

Correlation of MCM7 gene expression with TCGA tumor prognosis. (A) Association of MCM7 expression with patient OS. (B) Association of MCM7 expression with patient DFS.

Survival analysis was further performed via the Kaplan–Meier Plotter database. High MCM7 expression was associated with shortened OS in LIHC, LUAD and SARC, whereas it correlated with improved OS in CESC, LUSC, OV, READ, THYM and THCA (Supplementary Figure S1A). Additionally, elevated MCM7 expression indicated adverse recurrence-free survival (RFS) outcomes in BRCA, LIHC, LUAD, LUSC, SARC and UCEC (Supplementary Figure S1B).

Collectively, these pan-cancer survival analyses demonstrate that MCM7 exerts predominantly oncogenic roles across various tumor types and that high MCM7 expression correlates with poor clinical outcomes in most cancers, further confirming its prognostic value in cancer.

3.3. Genetic alteration analysis

Genetic alterations play a critical role in tumor initiation and progression. We analyzed the genetic alterations of MCM7 in different tumor samples. We found that esophageal adenocarcinoma harbored the highest frequency of MCM7 genetic alteration across all tumor types, with all altered cases presenting copy number amplification (Figure 3A). Amplification was also the only genetic variation detected in all cases of CHOL, OV, TGCT and SARC (Figure 3A). Noticeable amplification events were detected in most cancer types (Figure 3A), which may drive significant upregulation of MCM7 mRNA and protein expression. The protein structure of MCM7 is illustrated in Figure 3B.

Figure 3.

Panel A shows a bar graph comparing alteration frequencies of MCM7 gene across various cancer types by mutation, structural variant, amplification, deep deletion, and multiple alterations. Panel B presents a ribbon diagram of the MCM7 protein structure with reference sequence and database identifiers. Panel C depicts a lollipop plot locating specific MCM7 mutations and their frequencies along the amino acid sequence, annotating cancer associations. Panel D is a Kaplan-Meier curve indicating overall survival probability between altered and unaltered groups, with the altered group having a lower survival probability. Panel E shows a Kaplan-Meier curve of disease-specific survival probability, similarly indicating lower survival for the altered group.

Mutational characteristics of MCM7 in TCGA tumors. (A) Mutation types of MCM7 across various tumor. (B) 3D structure of MCM7 protein. (C) Mutation sites of MCM7. (D) OS between GBM patients with MCM7 mutations and non-mutant GBM patients. (E) DSS between GBM patients with MCM7 mutations and non-mutant GBM patients.

We further characterized MCM7 mutation patterns and loci (Figure 3C). R72C/H site alterations were identified in one BRCA, one GBM and one UCEC case. R367 site alterations occurred in two BLCA and one CESC case. R52W and X532_splice site alterations were detected in one BRCA, one COAD and one UCEC case. Survival analysis revealed that GBM patients carrying the R72C/H mutation exhibited inferior OS and DSS (Figures 3D, E). These genomic analyses suggest that copy number amplification is the major genetic driver of MCM7 overexpression, and specific MCM7 mutation subtypes confer tumor-specific prognostic alterations.

3.4. Immune infiltration and immune checkpoint analysis

The tumor microenvironment (TME) regulates tumor proliferation, invasion, metastasis, drug resistance and immune escape, serving as a critical external condition that profoundly affects tumor biological behaviors and therapeutic sensitivity (20, 21). Immune cell infiltration, an essential component of the tumor microenvironment, is closely correlated with tumor progression (22). To explore the role of MCM7 in immune mechanisms and responses within the TME, we analyzed the correlations between MCM7 expression and tumor mutational burden (TMB) and microsatellite instability (MSI). MCM7 expression was positively correlated with TMB and MSI in most tumor types. Specifically, significant positive correlations between MCM7 and TMB were observed in ACC, STAD, LUAD, LGG and PAAD (Figure 4A), while notable positive associations between MCM7 and MSI existed in SARC and CHOL (Figure 4B).

Figure 4.

Panel A shows a horizontal bar graph of correlation coefficients between TMB (tumor mutation burden) and various cancer types, with color indicating statistical significance; Panel B presents a similar graph for MSI (microsatellite instability); Panel C features heatmaps and scatter plots displaying the association between gene expression, immune cell infiltration scores, and purity across different cancers, with indicators for significance and partial correlation strength.

Correlations between MCM7 expression and tumor immune infiltration. (A) Correlations between MCM7 expression and TMB (B) Correlations between MCM7 expression and MSI. (C) Correlation between MCM7 expression and CAFs infiltration levels across TCGA tumor cohorts.

Cancer-associated fibroblasts (CAFs) play pivotal roles in the TME, modulating tumor progression, immune evasion, metastasis and therapeutic resistance (23). We further adopted EPIC, MCPCOUNTER, XCELL and TIDE algorithms to explore the correlation between MCM7 expression and CAF infiltration across various tumor types in the TCGA database. We observed that CAF infiltration exhibited a distinctly negative correlation with MCM7 expression in BRCA, HNSC-HPV+, SARC, TGCT and THYM across most or all algorithms. By contrast, a prominent positive correlation was found in ESCA, HNSC, HNSC-HPV-, KICH, KIRC, KIRP and skin cutaneous melanoma (SKCM) (Figure 4C).

Additionally, we analyzed the correlations between MCM7 expression and immunomodulatory genes and immune checkpoint genes. MCM7 was positively correlated with the majority of immunomodulatory genes, particularly in OV, KIPAN, KIRC, LIHC, and PRAD. Conversely, negative correlations between MCM7 and most immunomodulatory genes were observed in THYM, neuroblastoma (NB), and LUSC (Supplementary Figure S2A). When analyzing the correlation between MCM7 and 60 immune checkpoint genes, we found that MCM7 exhibited a significantly positive correlation with the stimulatory immune checkpoint gene HMGB1 in nearly all cancer types (Supplementary Figure S2B). This finding merits further investigation into whether MCM7 interacts with HMGB1 to facilitate immune activation within the tumor microenvironment. We also assessed the correlations between FANCD2 expression and three immune scores separately. StromalScore revealed that MCM7 expression was significantly negatively correlated with immune infiltration in GBM, BRCA, STES, SARC, LUSC and NB (Supplementary Figure S2C). ImmuneScore indicated a marked negative correlation between MCM7 level and immune infiltration in GBM, LUAD, STES, LUSC and wilms tumor (WT), while a positive correlation was observed in THYM (Supplementary Figure S2D). ESTIMATEScore showed significant negative correlations of MCM7 expression with immune infiltration in GBM, BRCA, LUAD, STES, STAD and LUSC (Supplementary Figure S2E). Taken together, MCM7 expression is closely associated with tumor genomic instability and stromal immune infiltration, revealing potential associations between MCM7 and tumour microenvironment features across multiple cancers.

3.5. RNA modification analysis

To explore the potential regulatory role of MCM7 in RNA epigenetic modifications across human cancers, we analyzed the correlations between MCM7 expression and 40 key regulators of three major RNA modifications (m¹A, m5C, and m6A) using TCGA pan-cancer datasets. As shown in Supplementary Figure S3 MCM7 expression was predominantly positively correlated with the expression of these RNA modification regulators across nearly all evaluated cancer types. Notably, ALYREF, a key reader of m5C modification, exhibited a strong positive correlation with MCM7 across all cancer types analyzed, which merits further investigation in future studies.

3.6. Diagnostic value of MCM7

To evaluate the diagnostic potential of MCM7 expression for distinguishing tumor tissues from normal controls across human cancers, we performed receiver operating characteristic (ROC) curve analysis using TCGA pan-cancer datasets. As shown in Figure 5, MCM7 exhibited varying degrees of diagnostic accuracy across the evaluated malignancies. Particularly, MCM7 showed excellent diagnostic performance (AUC > 0.9) in various malignancies, including CESC, CHOL, COAD, COADREAD, DLBC, ESCA, HNSC, LIHC, LUAD, LUSC, SARC, and STAD. These results further validate MCM7 as a reliable pan-cancer biomarker with high clinical applicability for tumor identification.

Figure 5.

Grid of twenty-four receiver operating characteristic (ROC) curve plots labeled by cancer type abbreviations, each showing a light blue ROC curve, a dashed diagonal reference line, and area under the curve (AUC) values with confidence intervals for an MCMT model, used to assess classification performance across cancer types.

ROC curves of MCM7 expression in various tumor types were analyzed, and the AUC was calculated for each tumor to evaluate the diagnostic ability of MCM7.

3.7. Enrichment analysis of MCM7-related partners

To explore the potential biological processes regulated by MCM7 during tumor initiation and progression, we screened MCM7-binding proteins and MCM7-correlated genes. Fifty MCM7-interacting proteins were retrieved from the STRING database to construct the PPI network of MCM7 (Supplementary Figure S4A). Using the GEPIA2 platform, expression correlation analysis was performed on TCGA dataset to identify the top 100 genes with expression positively correlated to MCM7. Scatter plots revealed that MCM7 expression was significantly positively correlated with RAD54L, RFC2, RAD51, KIFC1, MCM6 and TIMELESS in tumor tissues (Supplementary Figure S4B), which was further validated by corresponding correlation heatmaps (Supplementary Figure S4C). All identified MCM7-binding proteins and correlated genes were pooled for subsequent GO functional enrichment and KEGG pathway enrichment analyses. GO enrichment demonstrated that these genes were prominently enriched in biological processes including the G1/S transition of mitotic cell cycle, mitotic cell cycle progression, cell division and DNA replication (Supplementary Figure S4D). Consistently, KEGG enrichment analysis identified significant enrichment in the Cell cycle and DNA replication pathways (Supplementary Figure S4E). Collectively, these findings indicate that MCM7 is tightly implicated in the cell cycle regulation of tumor cells.

3.8. MCM7 is highly expressed in LUAD and is associated with poor prognosis

Pan-cancer analysis revealed significant upregulation of MCM7 in most tumor tissues versus paired normal tissues, implying that dysregulated MCM7 expression is a universal molecular feature across various tumors and exerts widespread oncogenic effects. Prognostic analysis further confirmed that MCM7 expression was tightly linked to patient survival, supporting its potential role as a prognostic biomarker. Pan-cancer analyses confirmed the tumor relevance and clinical significance of MCM7, but cellular functional validation is still lacking. Our data revealed that MCM7 was upregulated at both mRNA and protein levels in LUAD versus normal tissues. Its expression correlated with tumor stage, and high MCM7 expression was associated with shorter OS and RFS. On this basis, we conducted in vitro functional assays in LUAD to lay an experimental foundation for identifying promising therapeutic targets for LUAD.

3.9. MCM7 promotes LUAD cell proliferation and inhibits apoptosis

First, we performed Western blot analysis to detect the expression of MCM7 in the normal human bronchial epithelial cell line HBE, as well as lung adenocarcinoma cell lines PC-9, A549 and non-small cell lung cancer cell line H1299. Compared with normal human bronchial epithelial HBE cells, the expression of MCM7 was markedly upregulated in A549 and H1299 lung cancer cells (Figure 6A). Accordingly, we performed siRNA-mediated knockdown of MCM7 in these two cell lines, and satisfactory knockdown efficiency was achieved (Figures 6B, C). Clone formation assays revealed that knockdown of MCM7 markedly suppressed the proliferative capacity of A549 and H1299 cells (Figures 6D, E). Consistently, CCK-8 assays also demonstrated that MCM7 silencing reduced the proliferative activity of these two cell lines (Figures 6F, G).

Figure 6.

Western blot analyses, colony formation assays, cell proliferation curves, cell cycle flow cytometry histograms, and bar graphs compare MCM7 expression, clonogenicity, proliferation, and cell cycle distribution in A549 and H1299 lung cancer cells following MCM7 knockdown with two different siRNAs versus control, showing decreased MCM7 and cell cycle protein levels, reduced colony formation and proliferation, and altered cell cycle distribution upon MCM7 silencing.

MCM7 facilitates the proliferation of LUAD cells by accelerating cell cycle progression. (A) Western blot detection of MCM7 expression in LUAD cells. (B) Verification of the knockdown efficiency of MCM7 siRNA in A549 cells. (C) Verification of the knockdown efficiency of MCM7 siRNA in H1299 cells. Colony formation assay to explore the effect of MCM7 knockdown on proliferation of A549 (D) and H1299 (E) cells. CCK-8 analysis of cell viability following MCM7 knockdown in A549 (F) and H1299 (G) cells. Flow cytometry to explore the effect of MCM7 knockdown on cell cycle distribution in A549 (H) and H1299 (I) cells. Western blot analysis to verify the influence of MCM7 knockdown on the expression of cell cycle-related proteins in A549 (J) and H1299 (K) cell lines. Data are presented as mean ± SD. **p < 0.01, and ***p < 0.001 represent varying degrees of significance between the indicated groups.

Our previous analyses revealed that MCM7 is tightly associated with cell cycle regulation in tumor cells, implying that MCM7 may accelerate tumor proliferation by driving cell cycle progression (Supplementary Figures S4D, E). Accordingly, we applied flow cytometry to assess the regulatory effect of MCM7 on cell cycle distribution in A549 and H1299 cells. We found that MCM7 knockdown markedly elevated the proportion of A549 and H1299 cells in the G0/G1 phase, accompanied by a pronounced reduction in the percentage of S-phase cells, whereas no obvious change was observed in the G2/M cell population (Figures 6H, I). These findings indicate that MCM7 depletion suppresses LUAD cell proliferation by triggering cell cycle arrest at the G0/G1 checkpoint. Meanwhile, we further examined the expression of core cell cycle markers via Western blot. The results revealed that MCM7 knockdown diminished the protein levels of CDK2, Cyclin D1 and Cyclin E1 (Figures 6J, K). This finding further validated our flow cytometry data, illustrating that MCM7 silencing arrests cell cycle progression at the G0/G1 checkpoint by repressing the Cyclin D1-CDK2 axis, ultimately restraining the proliferation of LUAD cells.

3.10. MCM7 promotes invasion and migration of LUAD cells

To explore the effects of MCM7 on the invasion and migration of LUAD cells, transwell assays and wound healing assays were performed. Transwell results showed that MCM7 knockdown significantly suppressed the migration and invasion capacities of A549 and H1299 cells (Figures 7A, B). Consistently, wound healing assays verified that silencing MCM7 impaired the migratory ability of these two cell lines (Figures 7C, D). Epithelial–mesenchymal transition (EMT) is one of the pivotal molecular processes driving cancer progression. It induces cytoskeletal remodeling, morphological changes, and weakened intercellular adhesion in tumor cells, thereby promoting tumor invasion and metastasis (24, 25). For this reason, we examined the expression of EMT markers in A549 and H1299 cells. MCM7 knockdown significantly upregulated E-cadherin expression and downregulated the levels of N-cadherin and Vimentin (Figures 7E, F). Loss of E-cadherin constitutes an early event of EMT, whereas N-cadherin and Vimentin serve as crucial molecules responsible for EMT-mediated tumor metastasis (26). Collectively, MCM7 may facilitate tumor metastasis by activating EMT.

Figure 7.

Multipanel scientific figure presenting results from migration, invasion, wound healing, and western blot assays for A549 and H1299 cells with siNC, siMCM7-1, and siMCM7-2 treatments. Panels A and B show stained cell images and bar graphs comparing cell migration and invasion. Panels C and D display wound healing assay images at zero and thirty-six hours with quantitative bar graphs. Panels E and F show western blot bands and corresponding bar graphs quantifying E-cadherin, N-cadherin, vimentin, and MCM7 protein expression levels normalized to β-actin for both cell lines. Statistically significant differences are marked with asterisks.

Effects of MCM7 on migration and invasion of LUAD cell lines. Transwell assays to verify the effect of MCM7 knockdown on migratory and invasive capacities of A549 (A) and H1299 (B) cells. Wound healing assays to validate the effect of MCM7 knockdown on the migratory ability of A549 (C) and H1299 (D) cells. Western blot analysis to verify the influence of MCM7 knockdown on the expression of EMT-related proteins in A549 (E) and H1299 (F) cell lines. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 represent varying degrees of significance between the indicated groups.

3.11. RNA-seq reveals MCM7-mediated regulation of the JAK-STAT signaling pathway

All the aforementioned analyses relied on data retrieved from public databases. To dissect the signaling pathways potentially modulated by MCM7 in LUAD, we performed transcriptome RNA-seq on A549 cells transfected with siNC and siMCM7-2. Differential gene expression analysis was performed to explore the transcriptional changes induced by MCM7 knockdown in LUAD cells. In comparison with the siNC group, a total of 1963 genes were significantly upregulated and 1196 genes were downregulated following siMCM7 transfection. The overall distribution of differentially expressed genes (DEGs) was visualized by volcano plot and hierarchical clustering heatmap (Figures 8A, B). To further elucidate the biological functions of these DEGs, we conducted GO and KEGG pathway enrichment analyses. GO biological process enrichment demonstrated that the DEGs were prominently enriched in immune response and inflammatory response, indicating that MCM7 is closely involved in the immunomodulatory processes of LUAD (Figure 8C). KEGG pathway analysis further revealed that the DEGs were significantly enriched in multiple inflammation- and immune-related signaling pathways, including the TNF signaling pathway, cytosolic DNA-sensing pathway, IL-17 signaling pathway, NF-κB signaling pathway, and JAK-STAT signaling pathway (Figure 8D). Collectively, these results suggest that MCM7 may regulate the immune inflammatory microenvironment of LUAD by modulating the above key signaling cascades.

Figure 8.

Panel A shows a volcano plot indicating differential gene expression with significant up- and down-regulated genes. Panel B shows a heatmap of hierarchical clustering between siNC and siMCM7 groups. Panel C contains three bar graphs illustrating gene ontology enrichment analysis: biological process, cellular component, and molecular function. Panel D presents a dot plot of KEGG pathway enrichment, highlighting the JAK-STAT signaling pathway. Panels E and F display western blot images with corresponding bar graphs quantifying protein expression of JAK1, JAK2, STAT3, MCM7, and their phosphorylated forms in A549 and H1299 cells, comparing siNC, siMCM7-1, and siMCM7-2 samples.

RNA-seq to explore potential signaling pathways regulated by MCM7 in LUAD. Volcano plot (A) and heatmap (B) showing DEGs between siNC and siMCM7 groups based on RNA-seq data. (C) GO functional enrichment analysis of DEGs. (D) KEGG pathway enrichment analysis of DEGs. Western blot analysis verifying the effect of MCM7 knockdown on the JAK-STAT3 signaling pathway in A549 (E) and H1299 (F) cells. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 represent varying degrees of significance between the indicated groups.

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is a conserved signaling network that bridges extracellular cytokine stimulation and nuclear transcriptional responses (27). Beyond its essential roles in regulating cell proliferation, differentiation, immune response and tissue homeostasis, dysregulated JAK/STAT signaling is critically involved in tumor progression, immune evasion and TME remodeling (28). Specifically, the JAK-STAT3 axis is widely implicated in cancer cell survival, immunosuppression, and persistent inflammatory activation within the TME (29). To further validate the regulatory relationship between MCM7 and the JAK-STAT3 pathway, we performed molecular validation experiments. Western blot results showed that knockdown of MCM7 markedly reduced the total and phosphorylated protein levels of JAK1 and JAK2, as well as the phosphorylation level of STAT3 in both A549 and H1299 cell lines (Figures 8E, F). These findings reveal that MCM7 silencing is associated with reduced JAK-STAT3 pathway activation in LUAD cells.

4. Discussion

DNA replication is a fundamental biological process for cell proliferation, and abnormal activation of DNA replication machinery is one of the core hallmarks of malignant tumors (30). As an essential subunit of the minichromosome maintenance complex, MCM7 is responsible for initiating DNA replication and maintaining genome stability during cell division (7, 31). In this study, we performed a comprehensive pan-cancer analysis of MCM7, integrating multi-omics data from TCGA, GTEx, and other public repositories with experimental validation in LUAD. Our findings establish MCM7 as a broadly upregulated oncogenic regulator across diverse tumor types, with significant prognostic implications and potential utility as a diagnostic biomarker. The consistent upregulation of MCM7 at both transcriptional and protein levels in the majority of cancers examined, coupled with its association with poor survival outcomes, reinforces the notion that dysregulated DNA replication licensing is a conserved hallmark of malignant progression (2, 32).

One of the key observations from our study is the heterogeneous yet predominantly unfavorable prognostic role of MCM7. While high MCM7 expression predicted poor overall survival in tumors such as ACC, LIHC, and LUAD, a protective effect was observed in THYM. This context-dependent prognostic value underscores the importance of tissue-specific tumor microenvironments and suggests that MCM7 may exert divergent functions depending on cellular context or genetic background (12). We speculate that neoplastic thymic epithelial cells retain partial physiological thymus-organizing functions; elevated MCM7 may reflect the proliferative status of less-aggressive neoplastic epithelial clones rather than bona fide malignant transformation. Nevertheless, we have not performed further experimental analyses to verify this hypothesis in THYM models. Even so, the predominance of adverse prognostic associations across various tumor types highlights the potential of MCM7 as a broad-spectrum prognostic marker. Our genetic alteration analysis revealed that copy number amplification is the major alteration type driving MCM7 upregulation, with notable frequencies in esophageal adenocarcinoma, CHOL, and OV. The identification of specific mutation hotspots such as R72C/H, along with its association with poor survival in GBM, suggests that certain MCM7 mutations may confer gain-of-function properties or enhanced protein stability (3). Further structural and functional studies are warranted to elucidate the molecular consequences of these mutations. The TME plays a critical role in modulating MCM7-associated oncogenic effects. Our immune infiltration analysis revealed cancer type-specific correlations between MCM7 expression and CAF infiltration, suggesting that MCM7 may contribute to desmoplastic reactions or immune exclusion in certain tumors (23, 33). The striking positive correlation between MCM7 and HMGB1 across nearly all cancer types is particularly intriguing. HMGB1 is a damage-associated molecular pattern (DAMP) molecule that can promote inflammation and immune activation (34). However, this association is limited to transcriptional data from bulk tumour transcriptomes. We have no protein-level evidence or protein-protein interaction assays to support physical interaction or functional synergy. Therefore, potential synergistic roles of MCM7 and HMGB1 in tumour immunity remain hypothetical. Similarly, the strong pan-cancer positive correlation between MCM7 and ALYREF, an m5C reader, originates purely from transcriptomic datasets and lacks experimental validation. This correlation only provides a hypothetical clue linking DNA replication machinery and RNA modification, which requires further laboratory follow-up. Functional enrichment analyses consistently linked MCM7 to cell cycle control and DNA replication, which aligns with its canonical role as a helicase component (35, 36). Our experimental validation in LUAD confirmed that MCM7 silencing induces G0/G1 arrest and downregulates Cyclin D1, CDK2, and Cyclin E1, consistent with previous reports in hepatocellular carcinoma (7). However, studies have revealed that the abundance of MCM proteins in mammalian cells far exceeds the actual demand at DNA replication origins (37). Moreover, the majority of MCM proteins do not colocalize with active DNA synthesis sites, a phenomenon termed the “MCM paradox” (38, 39). This observation leads us to hypothesize that MCM7 may exert additional biological functions beyond its canonical replication role. Accordingly, beyond its canonical role in cell cycle regulation, we performed RNA-seq profiling and uncovered a novel connection between MCM7 and the JAK–STAT3 signaling pathway. Western blot validation demonstrated that MCM7 knockdown reduces JAK1/2 and STAT3 phosphorylation. Given the central role of JAK-STAT3 in tumor immune evasion, inflammation, and survival (27, 40), this finding suggests that MCM7 may promote tumor progression not only through direct effects on proliferation but also via modulation of inflammatory and immune signaling within the TME. However, whether MCM7 directly regulates JAK/STAT pathway components or acts through upstream cytokines or epigenetic mechanisms requires further investigation.

These findings position MCM7 as a promising putative therapeutic candidate that warrants further pre-clinical exploration. Given the essential physiological role of MCM7 in normal DNA-replication licensing, systemic MCM7 inhibition carries a high risk of toxicity in rapidly dividing healthy tissues. Further in-vivo animal-model studies are urgently required to evaluate tumour-specific targeting strategies, pharmacologic toxicity profiles, and potential synergy between MCM7-directed agents and immune-checkpoint-blockade or JAK-STAT-pathway inhibitors.

Several limitations of this study should be acknowledged. First, although our pan-cancer analyses are comprehensive, they are largely correlative and derived from bulk tissue transcriptomes, which may obscure cell-type-specific effects. Single-cell resolution studies would be valuable to delineate MCM7 expression patterns across malignant, stromal, and immune compartments. Second, our in vitro functional validation was limited to LUAD; future studies should extend to other cancer types where MCM7 exhibits strong prognostic significance, such as LIHC and ACC. Third, the mechanistic link between MCM7 and JAK-STAT3 signalling remains correlative in our current study. MCM7 knockdown reduces JAK1/2 and STAT3 phosphorylation, yet these changes could represent indirect downstream consequences of suppressed cell proliferation and cell-cycle arrest rather than direct pathway modulation. Rescue experiments using JAK-STAT3 pathway agonists are needed to formally validate causal regulation. Fourth, in-vivo animal models are absent in this work. Animal-based assays are needed to assess the therapeutic potential, pharmacologic toxicity, and tumour-specific effects of targeting MCM7 before drawing any therapeutic conclusions. Fifth, our hypothesis for combinatorial strategies combining MCM7-targeted intervention with immunotherapy lacks supporting experimental evidence. We have not performed immune-tumour cell co-culture or other immune-functional assays within the scope of current study. Finally, in addition to the JAK-STAT3 signalling axis, our RNA-seq analysis also identified enrichment of TNF, IL-17 and NF-κB pathways upon MCM7 perturbation. These inflammatory cascades are well-established drivers of lung tumour progression and immune microenvironment reprogramming. While the present work primarily focuses on the non-canonical function of MCM7 via JAK-STAT3, we cannot exclude the possibility that TNF, IL-17 and NF-κB signalling may also partially mediate MCM7-associated oncogenic phenotypes in LUAD. Further mechanistic dissection is warranted to delineate the crosstalk among these inflammatory pathways downstream of MCM7.

In conclusion, this pan-cancer study provides a comprehensive resource on the oncogenic roles of MCM7, highlighting its diagnostic, prognostic, and immunomodulatory significance across human cancers. Functional validation in LUAD confirms that MCM7 promotes malignant phenotypes through cell cycle regulation and JAK-STAT3 signaling. These findings identify MCM7 as a promising putative biomarker; the possibility of MCM7-directed intervention combined with immune checkpoint blockade or JAK/STAT-pathway inhibitors remains a hypothetical pre-clinical direction that requires extensive further experimental exploration.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Capital Medical Development and Research Special Project (Z201100005520090) and the Beijing Medical Management Center training program (PX20250806).

Footnotes

Edited by: Wenbo Ma, Southern Medical University, China

Reviewed by: Dengwang Chen, Zunyi Medical University, China

Lin Zhou, Changsha Medical University, China

Data availability statement

The data presented in the study are deposited in the NCBI Sequence Read Archive (SRA) repository, accession number PRJNA1550204.

Ethics statement

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.

Author contributions

XX: Data curation, Formal analysis, Investigation, Software, Visualization, Writing – original draft, Writing – review & editing. JeL: Data curation, Software, Visualization, Writing – original draft. YJ: Data curation, Software, Visualization, Writing – original draft. YZ: Validation, Visualization, Writing – review & editing. JoL: Validation, Visualization, Writing – review & editing. FC: Resources, Supervision, Writing – review & editing. FL: Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2026.1949632/full#supplementary-material

SupplementaryFile1.docx (3.4MB, docx)

References

  • 1. Safaroghli-Azar A, Mekonnen LB, Lenjisa J, Milne R, Wang S. Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors. J Hematol Oncol. (2026) 19(1):31. doi:  10.1186/s13045-026-01794-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Dequeker BJH, Scherr MJ, Brandão HB, Gassler J, Powell S, Gaspar I, et al. MCM complexes are barriers that restrict cohesin-mediated loop extrusion. Nature. (2022) 606:197–203. doi:  10.1038/s41586-022-04730-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Shi Q, Xu G, Jiang Y, Yang J, Han X, Wang Q, et al. Phospholipase PLCE1 promotes transcription and phosphorylation of MCM7 to drive tumor progression in esophageal cancer. Cancer Res. (2024) 84:560–76. doi:  10.1158/0008-5472.CAN-23-1633 [DOI] [PubMed] [Google Scholar]
  • 4. Wang J, Amin A, Cheung MH, Shi L, Liang C. Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells. Cancer Lett. (2022) 539:215677. doi:  10.1016/j.canlet.2022.215677 [DOI] [PubMed] [Google Scholar]
  • 5. Głuchowska KM, Hofman B. The role of MCM7 and its hosted miR-106b-25 cluster in renal cancer progression. Int J Mol Sci. (2025) 26:8618. doi:  10.3390/ijms26178618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Mo L, Su B, Xu L, Hu Z, Li H, Du H, et al. MCM7 supports the stemness of bladder cancer stem-like cells by enhancing autophagic flux. iScience. (2022) 25:105029. doi:  10.1016/j.isci.2022.105029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Qu K, Wang Z, Fan H, Li J, Liu J, Li P, et al. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis. (2017) 8:e2603. doi:  10.1038/cddis.2016.352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Lashen AG, Toss MS, Rutland CS, Green AR, Mongan NP, Rakha E. Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer. Pathobiology. (2024) 92:18–27. doi:  10.1159/000540790 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Li F, Liu G, Wang J, Luo Z. Integrated bioinformatic and machine learning analysis identifies MCM7 and ADAM17 as potential biomarkers for early stage gastric cancer. J Gastrointest Oncol. (2025) 16:1862–77. doi:  10.21037/jgo-2025-604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Yang J-Y, Li D, Zhang Y, Guan B-X, Gao P, Zhou X-C, et al. The expression of MCM7 is a useful biomarker in the early diagnostic of gastric cancer. Pathol Oncol Res. (2017) 24:367–72. doi:  10.1007/s12253-017-0251-1 [DOI] [PubMed] [Google Scholar]
  • 11. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol. (2004) 57:1057–62. doi:  10.1136/jcp.2004.016436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. (2023) 618:598–606. doi:  10.1038/s41586-023-06130-4 [DOI] [PubMed] [Google Scholar]
  • 13. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi:  10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  • 14. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. (2021) 398:535–54. doi:  10.1016/s0140-6736(21)00312-3 [DOI] [PubMed] [Google Scholar]
  • 15. Mantilla JG, Moreira AL. The grading system for lung adenocarcinoma: Brief review of its prognostic performance and future directions. Adv Anat Pathol. (2024) 31:283–8. doi:  10.1097/pap.0000000000000452 [DOI] [PubMed] [Google Scholar]
  • 16. Toyokawa G, Masuda K, Daigo Y, Cho H-S, Yoshimatsu M, Takawa M, et al. Minichromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer. (2011) 10:65. doi:  10.1186/1476-4598-10-65 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Liu Y-Z, Jiang Y-Y, Hao J-J, Lu S-S, Zhang T-T, Shang L, et al. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC). Lung Cancer. (2012) 77:176–82. doi:  10.1016/j.lungcan.2012.03.001 [DOI] [PubMed] [Google Scholar]
  • 18. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. (2019) 47:W556–60. doi:  10.1093/nar/gkz430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. (2019) 10:5679. doi:  10.1038/s41467-019-13528-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Wang M, Dong W, Chen J, Zhou Z, Fu S, Wu T, et al. T-cell exhaustion in the tumor microenvironment: Subcellular dysfunction, pan-cancer characteristics, and therapeutic interventions. Adv Sci (Weinh). (2026) 13(33):e75651. doi:  10.1002/advs.75651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Wang W, Liu X, Yan Z, Yan K, Zhou M, Yang Y, et al. Tumor microenvironment activatable immunomodulator for cancer immunotherapy. J Control Release. (2026) 395:114949. doi:  10.1016/j.jconrel.2026.114949 [DOI] [PubMed] [Google Scholar]
  • 22. Kim TH, Lim SH, Lee H, Chae YC, Min DS. Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver. Exp Mol Med. (2026) 58:366–81. doi:  10.1038/s12276-026-01650-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Zhang Z, Wang R, Chen L. Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy. J Nanobiotechnology. (2026) 24(1):689. doi:  10.1186/s12951-026-04567-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, et al. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms. Cell Prolif. (2023) 56:e13423. doi:  10.1111/cpr.13423 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Sleeman JP, Thiery JP. SnapShot: The epithelial-mesenchymal transition. Cell. (2011) 145:162:e1. doi:  10.1016/j.cell.2011.03.029 [DOI] [PubMed] [Google Scholar]
  • 26. Xie X, Zhao Y, Liu J, Li H, Zhu X, Liu Y, et al. ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. Cell Death Dis. (2025) 16:596. doi:  10.1038/s41419-025-07889-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. (2023) 8:204. doi:  10.1038/s41392-023-01468-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Zhang X, Li P, Ma F, Wang T, Chu Q, Wei S, et al. JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention. Mol Cancer. (2026) 25(1):173. doi:  10.1186/s12943-026-02692-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. (2015) 66:311–28. doi:  10.1146/annurev-med-051113-024537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Lo N, Kim H. Tilting the balance of life and death: navigating DNA replication stress in cancer therapy. Exp Mol Med. (2026) 58(6):1721–33. doi:  10.1038/s12276-026-01745-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Forsburg SL. Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev. (2004) 68:109–31. doi:  10.1128/mmbr.68.1.109-131.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. (2022) 12:31–46. doi:  10.1158/2159-8290.cd-21-1059 [DOI] [PubMed] [Google Scholar]
  • 33. Wang S, Wang D, Zhou Y, Li W, Sun G, Cao L, et al. Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy. Exp Hematol Oncol. (2026) 15(1):70. doi:  10.1186/s40164-026-00783-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Ma M, Zhang H, Deng W, Du X, Chen M, Chen D, et al. HMGB1-mediated formation of IL-33-abundant NETs drives lung-to-kidney injury in severe pneumonia-associated acute kidney injury. JCI Insight. (2026) 11:e191979. doi:  10.1172/jci.insight.191979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Bolhuis DL, Fleifel D, Bonacci T, Wang X, Mouery BL, Cook JG, et al. USP37 prevents unscheduled replisome unloading through MCM complex deubiquitination. Nat Commun. (2025) 16:4575. doi:  10.1038/s41467-025-59770-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Duan H, Wang S, Shu W-J, Tong Y, Long H-Z, Li G, et al. SETD3-mediated histidine methylation of MCM7 regulates DNA replication by facilitating chromatin loading of MCM. Sci China Life Sci. (2024) 68:793–808. doi:  10.1007/s11427-023-2600-0 [DOI] [PubMed] [Google Scholar]
  • 37. Wang C, Ye M, Xu T, Feng J, Zhang J, Yang W, et al. MCM7 promotes liver fibrosis by transcriptionally regulating IL11 via the SHCBP1-RACGAP1-STAT3 axis. Cell Death Dis. (2025) 16:608. doi:  10.1038/s41419-025-07937-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Li J, Dong J, Wang W, Yu D, Fan X, Hui YC, et al. The human pre-replication complex is an open complex. Cell. (2023) 186:98–111. doi:  10.1016/j.cell.2022.12.008 [DOI] [PubMed] [Google Scholar]
  • 39. Sun Q, Sui Y, Li S, Zhou R, Fu Z, Luo J, et al. RNF8-mediated multi-ubiquitination of MCM7: Linking disassembly of the CMG helicase with DNA damage response in human cells. Life Sci. (2024) 353:122912. doi:  10.1016/j.lfs.2024.122912 [DOI] [PubMed] [Google Scholar]
  • 40. Mohamed J, Ezat H, Abdelrahman R, Abdelaziz R, Ayman R, Oy E-K, et al. The JAK/STAT pathway: key mechanism in gene activation, disease regulation, and emerging therapeutic targets. Mol Biol Rep. (2026) 53:732. doi:  10.1007/s11033-026-11847-2 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SupplementaryFile1.docx (3.4MB, docx)

Data Availability Statement

The data presented in the study are deposited in the NCBI Sequence Read Archive (SRA) repository, accession number PRJNA1550204.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES